Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 135 recruiting now early-phase tilt #31 of 28,707 conditions

Parkinson Disease: early-phase trial registry

135 of 298 indexed Parkinson Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #31 of 28,707 conditions by registered trial count.

298 US clinical trials · 135 currently recruiting · #31 of 28,707 conditions by registered trial count

Parkinson Disease: 298 US clinical trials tracked, 135 recruiting.

Parkinson Disease is the subject of 298 registered US clinical trials on ClinicalTrials.gov, 135 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 66 in Phase 1-2 (earlier-stage). The most active sponsor is University of Minnesota, running 10 of these trials.

Enrollment posture brief

Registry condition parkinson-disease

OPEN 135 | RECR 45% | LATE 21 | EARLY 66 | RANK #31 | SPON 10

Nearest open-share peer: Gastric Cancer (45% recruiting · 159 trials)

Chronic Pain46%Parkinson Disease (this)45%Cardiovascular Diseases44.1%HIV35.9%COVID-1922.7%
Open-enrollment share among volume-matched conditions near Parkinson Disease

Parkinson Disease lists 135 open slots (45% of 298 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Parkinson Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Parkinson Disease is recruiting above its size-band peers.

    135 of 298 indexed trials (45.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Parkinson Disease trials is spread across many organizations.

    University of Minnesota accounts for 10 of 298 trials (3.4%). 165 distinct sponsors appear on at least one study for this condition label.

  3. Most Parkinson Disease trials plan to enrol fewer than 100 people.

    Median target enrolment is 55 among the 298 trials that report a genuine target (sentinel values excluded). 207 of those (69.5%) plan for fewer than 100 participants.

  4. Parkinson Disease research is mostly interventional.

    226 interventional and 72 observational studies make up this index (75.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 131Phase 235Phase 38Phase 413

Open and recent trials

298 total, page 5 of 6

COMPLETED Phase 2 129 participants

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Novartis Pharmaceuticals

NCT01491932

COMPLETED NA 128 participants

Study in Parkinson's Disease of Exercise

University of Colorado, Denver

NCT01506479

COMPLETED NA 120 participants

Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients

National Institute of Mental Health (NIMH)

NCT00004451

COMPLETED 114 participants

Fox BioNet Project: LRRK2-002

Michael J. Fox Foundation for Parkinson's Research

NCT03545425

COMPLETED NA 112 participants

Driving Performance of People With Parkinson's Using Autonomous In-Vehicle Technologies

University of Florida

NCT04660500

COMPLETED Phase 1 110 participants

A Study to Investigate a New Treatment in Patients With Parkinson's Disease

Tools4Patient

NCT03407378

COMPLETED NA 108 participants

Movement-2-Music: Lakeshore Examination of Activity, Disability, and Exercise Response Study

University of Alabama at Birmingham

NCT03797378

COMPLETED NA 104 participants

Effects of Aerobic Exercise in Parkinson's Disease

US Department of Veterans Affairs

NCT00784563

COMPLETED 97 participants

The Benefits of Nature for Mood and Cognition in Persons With and Without Parkinson's Disease

Boston University Charles River Campus

NCT06483126

COMPLETED Phase 2 94 participants

GM1 Ganglioside Effects on Parkinson's Disease

Thomas Jefferson University

NCT00037830

COMPLETED 89 participants

Biomarkers of Risk of Parkinson Disease

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00775853

COMPLETED Phase 1 82 participants

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

Weill Medical College of Cornell University

NCT03675282

COMPLETED 81 participants

PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2)

Indiana University

NCT01536821

COMPLETED 80 participants

Transcranial Magnetic Stimulation in Parkinson's Disease

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00023062

COMPLETED Phase 2 79 participants

A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

Alkahest

NCT03713957

COMPLETED Phase 3 77 participants

Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease

VA Office of Research and Development

NCT03149809

COMPLETED 72 participants

GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology

ConvaTec

NCT05470751

COMPLETED NA 72 participants

Visual Spatial Exploration and Art Therapy Intervention in Patients Diagnosed With Parkinson's Disease

NYU Langone Health

NCT03178786

COMPLETED Phase 2 64 participants

A Study of TAK-071 in People With Parkinson Disease

Takeda

NCT04334317

COMPLETED 63 participants

Brain Networks and Consciousness

University of Texas Southwestern Medical Center

NCT04502550

COMPLETED Phase 2 62 participants

PD4PD:Partnered Dance for Parkinson Disease

Washington University School of Medicine

NCT01388556

COMPLETED Phase 2 62 participants

Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families

Institute for Neurodegenerative Disorders

NCT00273351

COMPLETED Phase 1 60 participants

Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease

Sun Pharma Advanced Research Company Limited

NCT02970019

COMPLETED Phase 2 60 participants

Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)

Hope Biosciences Research Foundation

NCT04995081

COMPLETED 58 participants

Speech, Linguistic and Acoustic Markers in Parkinson's Disease

University of Massachusetts, Worcester

NCT04273672

COMPLETED Phase 1 57 participants

Lu AF28996 in Participants With Parkinson's Disease (PD)

H. Lundbeck A/S

NCT04291859

COMPLETED 54 participants

FoxBioNet Pilot Project: SAVE (Synuclein Assay Validation Effort)

Michael J. Fox Foundation for Parkinson's Research

NCT03170063

COMPLETED NA 51 participants

Physiological Effects of Nutritional Support in Patients With Parkinson's Disease

Thomas Jefferson University

NCT02445651

COMPLETED Phase 2 51 participants

Dual-task Augmented Reality Treatment for Parkinson's Disease

The Cleveland Clinic

NCT04634331

COMPLETED NA 50 participants

Pre-Active PD: Looking At Physical Activity Behavior Change in Parkinson's Disease

San Jose State University

NCT05308238

COMPLETED Phase 4 50 participants

Naltrexone for Impulse Control Disorders in Parkinson's Disease

University of Pennsylvania

NCT01052831

COMPLETED 48 participants

Determining the Microbiota Composition of the Middle Meatus in Parkinson's

Rush University Medical Center

NCT03336697

COMPLETED NA 46 participants

Emotion Study/Substudy: Flexible Brain Study

University of Florida

NCT03872414

COMPLETED 45 participants

The Influence of Sensory Stimuli on Gait Imagery in Patients With Freezing of Gait

National Institute of Neurological Disorders and Stroke (NINDS)

NCT01071590

COMPLETED NA 41 participants

Strength Training and Medication Effects in Parkinson Disease Effects on Hypokinesia in Parkinson Disease

University of Utah

NCT00665184

COMPLETED 40 participants

Cognitive Disparities in Parkinson's Disease

Duke University

NCT07262658

COMPLETED Phase 2 40 participants

Levetiracetam Treatment of L-dopa Induced Dyskinesias

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00076674

COMPLETED Phase 3 40 participants

Embryonic Dopamine Cell Implants for Parkinson's Disease

University of Colorado, Denver

NCT00038116

COMPLETED NA 40 participants

Transcutaneous Afferent Patterned Stimulation (TAPS) for Reduction of Parkinson's Disease (PD) Related Action Tremor

Cala Health

NCT05012579

COMPLETED Phase 1 40 participants

A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

Luye Pharma Group

NCT03733561

COMPLETED 40 participants

Investigation of Effects of Delayed Feedback on Non-motor Symptoms in Individuals With Parkinson's Disease

Kessler Foundation

NCT06217484

COMPLETED NA 38 participants

Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology

University of Alabama at Birmingham

NCT03409120

COMPLETED NA 35 participants

Golf Instruction Versus Tai Chi for People With Parkinson's Disease

Massachusetts General Hospital

NCT03563807

COMPLETED NA 35 participants

Protective Step Training in Parkinson's Disease

Arizona State University

NCT03895814

COMPLETED NA 35 participants

Training and Parkinson's

University of Miami

NCT03434327

COMPLETED NA 33 participants

Effect of Osteopathic Manipulative Medicine on Parkinson Disease

New York Institute of Technology

NCT02107638

COMPLETED NA 33 participants

Preparing Patient-Caregiver Dyads with Parkinson's Disease for Future Decision Making

Purdue University

NCT05084209

COMPLETED NA 32 participants

Treadmill Training in People With Parkinson's Disease

Georgia State University

NCT05239026

COMPLETED NA 32 participants

Tai Chi for Enhancing Motor and Cognitive Function in Parkinson's Disease

Harvard University Faculty of Medicine

NCT02418780

COMPLETED Phase 2 31 participants

Intranasal Insulin in Parkinson's Disease

HealthPartners Institute

NCT04251585

← Previous Page 5 of 6 Next →

Phase Distribution

PhaseTrial count
Phase 1 31
Phase 2 35
Phase 3 8
Phase 4 13

Named interventions

Most-linked intervention names on Parkinson Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
18 trials
Placebo Other
7 trials
Tavapadon Drug
2 trials
Protective Step Training Behavioral
2 trials
Droxidopa Drug
2 trials
Crexont ER Drug
2 trials
Deep Brain Stimulation (DBS) Device
2 trials
Midodrine Drug
2 trials

US sites by state

Facility locations filed on Parkinson Disease trials. A trial with sites in several states counts in each.

California 62 trials
Florida 61 trials
New York 52 trials
Massachusetts 37 trials
Illinois 35 trials
Colorado 35 trials
Michigan 30 trials
Pennsylvania 25 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Parkinson Disease page

298 registered trials, 135 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Parkinson Disease condition card totals 298 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.